USX:NTRA - Natera Inc (USD 45.01) Natera, Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
   
Add Alert 


Yahoo Finance

USD 45.01    +1.530 (+3.52%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

2 Jun 2020


Overview

2 Jun 2020

Day Change: 1.530 (3.52%)

52 Wk Range: 16.87 - 49.22

Day's Range: 42.3575 - 45.4

Last Volume: 557,228

Current Yield: 0%

Projected Yield: 0%

Open: USD 43.29

2 Jun 2020

Metric NTRA S.Median
Beta 1.36 0.45
VaR 45.07 55.02
E.Shortfall 70.44 89.56
Liquidity 858.8K 2,718.04

Fundamental

2 Jun 2020

PE: -26.104

Market Cap: 3.2B

Price Over Book: 37.443

Price Over Sales: 11.09

Return On Assets: -31.9%

Return On Equity: -143.4%

Current Ratio: 2.346

General

CEO: Dr. Matthew Rabinowitz

IPO: 2015-07-02

Headquarters: US

Employees: 1,039

Sector: Health Technology

Industry: Medical Specialties

Useful Links
Homepage

Description

Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center; and a partnership agreement with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays for use by biopharmaceutical and clinical customers. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.